Board of Directors

  • Domenic Serafino

    Chief Executive Officer and Director
    Domenic Serafino has served as Venus Concept’s Chief Executive Officer since June 2010 and as Chairman of its board of directors since May 2014. Before joining Venus Concept in late 2010, Mr. Serafino served as President of Syneron Medical Ltd. from 2001 to 2007, during which time Syneron completed its initial public offering in the United States. Prior to Syneron, from 1995 to 2001, he served as a Partner, President, and Chief Operating Officer of Sigmacon Group. Mr. Serafino also serves on the board of directors of Titan Medical Inc. (NASDAQ:TMDI) since September 2018, FB Dermatology since October 2018 and Scientus Pharma Inc. since October 2013. Mr. Serafino is also a member of the board of directors of Venus Concept’s subsidiaries in Australia, Singapore, Hong Kong, Israel, Shanghai (Chairman and Legal Representative), United Kingdom, Argentina, Mexico (President), South Africa, Canada (Chairman and Chief Executive Officer), Italy, Japan, United States of America, South Korea (President and Representative Director), and France (Chief Executive Officer and President). Mr. Serafino earned a degree in Business Administration from Centennial College.
    • Scott Barry

      Director and Chairman of the Board
      Scott Barry has served as a member of Venus Concept’s board of directors since June 2017. Mr. Barry joined EW Healthcare Partners in 2006 and has been a Managing Director of EW Healthcare Partners since 2012. Prior to joining EW Healthcare, Mr. Barry worked at Novartis Pharma AG where he most recently served as the Global Head of Pharma M&A and Collaborations. He was responsible for global acquisitions, equity investments and corporate partnerships across all therapeutic areas. Prior to joining Novartis, Mr. Barry was a director for Century Capital Associates LLC, a boutique healthcare investment bank and consulting firm, where he focused on mergers and acquisitions, strategic partnering and financing transactions. Previously, he held positions at KPMG LLP in their healthcare, corporate finance, and assurance services groups. Mr. Barry serves as a director of a number of EW Healthcare portfolio companies including Breg, Inc., Encore Dermatology, Inc., and Metabolon, Inc. He previously served on the boards of Orthovita Inc. (NASDAQ:VITA), which was acquired by Stryker Corporation, Victory Pharma, Inc., which was acquired by Shiongi, Inc., and Valcera, Inc., which was acquired by Perrigo Company plc. Mr. Barry has a Bachelor of Arts degree from Wesleyan University and a Master of Business Administration from New York University.
    • Juliet Tammenoms Bakker

      Director
      Juliet Tammenoms Bakker has served as a member of Venus Concept’s board of directors since May 2014. Ms. Tammenoms Bakker is a Founder and Managing Director of Longitude Capital Management where she focuses on investments in medical technology. Prior to joining Longitude, Ms. Tammenoms Bakker was a Managing Director of Pequot Ventures where she founded the life sciences investment practice. Prior to Pequot, she was Director of Strategic Planning and Director of Operations for Waste Management International, Inc. Previously she was a sell-side equity analyst with Banque Paribas. Ms. Tammenoms Bakker began her career as an investment banker in the corporate finance department at PaineWebber, Inc. She currently serves on the boards of Alphaeon Corporation, Axonics Modulation Technologies (NASDAQ:AXNX), DyaMX, Inc., Encore Dermatology, Inc., Nalu, and RxSight, Inc. She has previously served on the boards of Ablation Frontiers LLC (acquired by Medronic plc (NYSE:MDT)), AqueSye (acquired by Allergen plc (NYSE:AGN)) CryoVascular Systems, Inc. (NASDAQ:CSII) (acquired by Boston Scientific Corporation (NYSE:BSX)), Embolic Protection Devices (acquired by Boston Scientific Corporation), Enteric Medical (acquired by Boston Scientific Corporation), Eyeonics Inc. (acquired by Bausch+Lomb), Genyx Medical (acquired by C.R.Bard, Inc.), Insulet (PODD), Precision Dermatology, Inc. (acquired by Bausch Health Companies Inc. (NYSE: BHC) formerly, Valeant Pharmaceuticals), and Sadra Medical Inc. (acquired by Boston Scientific Corporation). Ms. Tammenoms Bakker holds an M.P.A. from the Harvard Kennedy School and a B.Sc. from the College of Agriculture and Life Sciences at Cornell University, or CALS, where she is a member of the CALS Advisory Council. Ms. Tammenoms Bakker is also a board member of the Boys and Girls Club of Greenwich.
    • Garheng Kong, M.D.

      Director
      Garheng Kong, M.D. has served as a member of Venus Concept’s board of directors since June 2017. Dr. Kong has been the managing partner of HealthQuest Capital, a healthcare investment firm, since July 2013. He was the general partner at Sofinnova Ventures, a venture firm focused on healthcare, from September 2010 to December 2013. From 2000 to September 2010, he was at Intersouth Partners, a venture capital firm, most recently as a general partner, where he was a founding investor or board member for multiple healthcare companies, several of which were acquired by large healthcare companies. Dr. Kong also serves on the board of directors of Avedro, inc. (NASDAQ:AVDR), a corneal health company, since 2018, Alimera Sciences, Inc. (NASDAQ:ALIM), a biopharmaceutical company, since October 2012, Laboratory Corporation of America Holdings (NYSE:LH), a healthcare company, since December 2013, StrongBridge BioPharma Plc (NASDAQ:SBBP) since September 2015 and Melinta Therapeutics, Inc. (NASDAQ:MLNT) since September 2006. Dr. Kong holds a B.S. from Stanford University and an M.D., Ph.D., and M.B.A. from Duke University.
    • Louise Lacchin

      Director
      Louise Lacchin has served as a member of Venus Concept’s board of directors and chair of the audit committee since August 2015. Prior to joining Venus Concept, Ms. Lacchin was a Director, Treasurer, and Chair of the finance committee at Sheena’s Place from October 2011 to May 2015. From 1983 to 2010 Ms. Lacchin held various positions with Loblaw, and its parent, George Weston Limited (OTCMKTS:WNGRF), or Weston. Most recently, from 2007 to 2010, Ms. Lacchin was Executive Vice President of Finance at Weston with direct responsibility over Weston’s and Loblaw’s corporate treasury, tax, insurance and risk, pension and benefits, commodity risk management departments, Weston’s financial reporting, corporate development, and other corporate office departments. Ms. Lacchin served as Chair of Weston’s disclosure committee from 2008 to 2010. In 2006, Ms. Lacchin was named one of the TOP 100™ Canada’s Most Powerful Women. Ms. Lacchin holds a B.A. in Economics and Accounting from Algoma University and an MBA in Accounting and Finance from McMaster University.
    • Fritz LaPorte

      Director
      Fritz LaPorte has served as a member of Venus Concept’s board of directors, chair of its compensation committee and member of its audit committee since August 2015. Mr. LaPorte is a Partner at Dovere Advisory Group, LLC, which he co-founded in October 2014 to guide early stage operating growth companies primarily in the medical device and healthcare sectors, in creating and sustaining value while reducing risk in the process. Mr. LaPorte co-founded MAKO Surgical Corp., an orthopedic surgical robotic company, in November 2004 and served as Senior Vice President, Chief Financial Officer, and Treasurer all the way through to December 2013. It was then acquired by Stryker Corporation (formerly NASDAQ:MAKO). Mr. LaPorte subsequently served as Vice President and Chief Financial Officer of Stryker Corporation – Stryker Mako Business Unit from December 2013 to June 2014 to assist in the integration of MAKO Surgical Corp. into Stryker Corporation. Since January 2018, he also serves on the board of directors and finance committee of Holy Cross Hospital in Fort Lauderdale, Florida. Mr. LaPorte holds a Bachelors of Business Administration in Accounting from Florida Atlantic University.
    • Frederic Moll, M.D

      Director
      Frederic Moll, M.D. has been a member and served as Chairman of Restoration Robotics’ board of directors since November 2002. Dr. Moll is also a co-founder, and, since September 2012, is the Chief Executive Officer of Auris Surgical Robotics, Inc. From 2002 to 2010, He served as the Chief Executive Officer of Hansen Medical, a medical robotics company, which he also co-founded. Previously, Dr. Moll co-founded Intuitive Surgical, Inc. and from 1995 to 2002 served as its first Chief Executive Officer. He also co-founded Origin Medisystems, Inc., which later became an operating company within Guidant Corp. following its acquisition by Eli Lilly & Co., and Endotherapeutics Corp. Dr. Moll serves on the board of directors of Biolase, Inc. and IntersectENT, Inc. He received a B.A. in economics from the University of California at Berkeley, an M.S. degree in managements from Stanford University and an M.D. from the University of Washington.
    • Anthony Natale, M.D.

      Director
      Anthony Natale, M.D. has served as a member of Venus Concept’s board of directors since December 2014. Dr. Natale has served as a Managing Partner at Aperture Venture Partners, a healthcare venture capital firm, since 2010. From 2002 to 2006 and 2006 to 2010, respectively, Dr. Natale was a Partner at MDS Capital and Prism Ventures, where he made and managed healthcare venture investments. He has been a founder, director and/or lead investor of numerous venture-backed life sciences companies. Dr. Natale currently serves on the board of directors of Channel Medsystems, Cortica, and Neuros Medical. He previously has had board roles at multiple investee companies, including Xlumena, Spirox, Mako Surgical, Inspire Medical, Avedro, Otonomy, and ENTrigue Surgical. He holds a B.A. from the University of Virginia, an M.D. from the University of Florida, and an M.B.A. from Yale University. Prior to transitioning into venture capital, Dr. Natale trained in General Surgery and Otolaryngology/Head and Neck Surgery at the University of Connecticut and Hartford Hospital.
    • Keith Sullivan

      Director
      Keith Sullivan has served as the Chief Commercial Officer of Restoration Robotics since November 2018 and as a member of the board of directors since July 2018. Mr. Sullivan previously served as Chief Commercial Officer and President (North America) of ZELTIQ Aesthetics, Inc., a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform under the Coolsculpting® brand, from January 2016 until the acquisition of ZELTIQ by Allergan, Inc. in April 2017. Mr. Sullivan previously served as Senior Vice President and Chief Commercial Officer of ZELTIQ from November 2014 until January 2016 and as Senior Vice President of Worldwide Sales and Marketing from July 2013 through October 2014. Mr. Sullivan, who has more than 30 years of senior sales leadership experience in the medical device industry, has previously held leadership positions with Medicis Pharmaceuticals, Reliant Technologies, Medtronic, Vision Quest Laser Center and Coherent Medical. Mr. Sullivan received a Bachelor of Business Administration from the College of William and Mary.